Detalhe da pesquisa
1.
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Br J Cancer
; 129(1): 38-45, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37120671
2.
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study.
BMC Med
; 21(1): 246, 2023 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37408015
3.
Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin.
Cancer Invest
; 39(6-7): 466-472, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34075851
4.
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma.
Br J Cancer
; 122(12): 1754-1759, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32265508
5.
Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.
Br J Cancer
; 121(3): 218-221, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31249394
6.
Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.
Br J Cancer
; 121(7): 625, 2019 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-31363170
7.
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Cell Rep Med
; 5(3): 101435, 2024 Mar 19.
Artigo
Inglês
| MEDLINE | ID: mdl-38417447
8.
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
J Immunother Cancer
; 11(6)2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37286303
9.
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review.
JACC CardioOncol
; 4(1): 1-18, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-35492830
10.
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Expert Rev Anticancer Ther
; 22(4): 383-400, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35260027
11.
Liquid Biopsy for Pancreatic Cancer Detection Using Infrared Spectroscopy.
Cancers (Basel)
; 14(13)2022 Jun 21.
Artigo
Inglês
| MEDLINE | ID: mdl-35804820
12.
Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients.
Am J Cancer Res
; 12(12): 5668-5683, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36628279
13.
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
Clin Cancer Res
; 27(14): 3926-3935, 2021 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33782030
14.
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Clin Cancer Res
; 27(17): 4848-4858, 2021 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34108184
15.
A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection.
Microsyst Nanoeng
; 7: 21, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34567735
16.
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma.
Liver Cancer
; 9(1): 93-104, 2020 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-32071913
17.
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Clin Cancer Res
; 26(22): 5869-5878, 2020 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32816891
18.
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance.
BMJ
; 383: e076386, 2023 10 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37863491
19.
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.
BMJ
; 383: e076387, 2023 10 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37863501
20.
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.
EMBO Mol Med
; 7(8): 1063-76, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-26077591